First AD

Second AD

Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in TN CLL

Video content above is prompted by the following:

One other frontline doublet or triplet therapy was from the AMPLIFY trial looking AVO or AV. Can you share some key highlights and your impressions so far?

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASH 2024: Updates in the Treatment of CLL  

Peer Exchange

Panelists discuss how the AMPLIFY trial evaluated acalabrutinib-venetoclax-obinutuzumab (AVO) vs acalabrutinib-venetoclax (AV) as frontline therapy options, highlighting the impressive depth of response with both regimens while noting the additional toxicity profile associated with the triplet combination.